Indra Sistemas (IDR.MC) — Investment Thesis #

Date: 2026-05-14 Price: EUR 50.50 | Forward P/E: 15.8x | Graham Score: 4/7 | Sector: Spanish Defense Electronics + IT

Hypothesis #

Indra is Spain's national defense electronics champion at the start of a structural multi-year ramp:

• Spain formally committed to 2.1% NATO defense spending (~EUR 24.6B/yr)
• Indra has won ~45% of PEM (Special Modernization Programs) totaling EUR 13B+ through 2037
• Q1 2026 order backlog: EUR 20.3B (+154% YoY), book-to-bill 2.14x
• Defense EBIT margin 18.1% — leads European peers (Hensoldt 8-10%, Thales 10-12%)
• Forward P/E 15.8x implies just 3.7% perpetual growth. Recent EBIT growth is +24% YoY in Q1

The mispricing thesis: A company growing EBIT 20%+ with a EUR 20B backlog priced as a 3.7% grower. Graham IV at 5% growth is EUR 59, at 7.5% is EUR 75, at 10% is EUR 91.

The defer thesis (why I'm not buying yet): Q1 2026 missed revenue consensus by ~9%. Management blamed "milestone timing" — defense revenues are lumpy because they recognize on program milestones, not steady deliveries. They guided H1 Defense >EUR 1B; Q1 Defense was EUR 275M. Q2 must therefore deliver EUR 725M+ to validate the timing explanation. Q2 results land late July / early August 2026. If Q2 validates, the entry case strengthens significantly. If Q2 misses too, the "timing" defense collapses to "structural delay" and the multiple gets re-rated downward.

What Changed (Why Now) #

1. Spain crossed the 2% NATO threshold (April 2025). Indra is the largest beneficiary — captured ~45% of the PEM (Programa Especial de Modernización) contract value: TESS howitzers (EUR 4.55B), COAAS air defense (EUR 2.03B), SDR tactical radios (EUR 1.42B), plus 4-5 smaller awards.

2. Q1 2026 results (April 30) were mixed. Revenue +14.6% but missed consensus by 9%. EBIT +24%. EBITDA margin expanded 380bps. Order intake +56% YoY, backlog +154%. The market sold off 4% on the revenue miss; the operational metrics were strong.

3. April 30 EDF awards. Indra leading 2 of 15 European Defence Fund projects (SHIMBAD radar, ECC2 cyber C2) from the EUR 799M round. Long-tail revenue stream into 2027+.

4. Governance: De los Mozos CEO renewed for 3 years (May 2). Removes succession risk. Industrial executive (ex-Renault manufacturing), not government appointee.

5. Governance: Escribano family (14.3%) board-seat fight unresolved. Reports from May 11 that Ángel Escribano is seeking 4 board seats (parity with SEPI's effective 4) as condition for any future re-engagement on M&A. This is an active governance overhang.

6. AQR Capital disclosed 3.39% short position on April 28 — post-Q1 miss. Sophisticated quant short. This is an informed bearish signal worth taking seriously per shr-002 (inverse).

Why Not Buy Today #

Three reasons defer makes more sense than deploy:

1. Q1 was a real miss. The timing explanation needs validation. #

Defense revenue Q1 = EUR 275M. Management guided H1 Defense > EUR 1B. That requires Q2 Defense ≥ EUR 725M — a 164% sequential acceleration. Either:

• The timing explanation is correct (PEM milestone payments cluster in Q2) → Q2 will print EUR 725M+ → thesis confirmed, stock re-rates
• The timing explanation is excuse-making → Q2 will print EUR 400-500M → guidance gets cut → multiple compresses

This is a binary verification due ~10-12 weeks from now. Buying ahead is speculation on which scenario plays out.

2. AQR's 3.39% short is informed. #

AQR is a sophisticated multi-factor fund. They disclosed (i.e., crossed the 0.5% CNMV threshold from below) AFTER the Q1 miss. They added in the face of the news. This is not a contrarian retail short; it's quantitative conviction backed by signals we don't have visibility on (factor exposures, earnings quality models, momentum reversal indicators).

Per shr-023, "high short interest building at lower prices means shorts are winning trades with conviction, not squeeze fuel." AQR is shorting at a level (EUR 47-50) where they expect further decline.

3. Governance overhang has a clear resolution timeline. #

The Escribano family's 4-seat demand will resolve at the next AGM or earlier via board action. Until resolved, the M&A optionality is contingent on whether Escribano gets the seats they're demanding. The CEO + Chair (Simón) need to navigate this. Buying into governance crisis is paying full price for an event that hasn't happened.

Why It's Still a Buy in 10-12 Weeks (Conditional) #

If Q2 validates:

• Defense revenue trajectory locks in at EUR 1.4-1.6B annually (5-6x Q1)
• Group EBIT 2026 hits >EUR 700M = 24% EPS growth
• Forward P/E compresses further to 12-13x at current price
• Analyst PT upgrades follow (current mean EUR 63.5)
• Re-rating to forward 18-20x (sector multiple) implies stock at EUR 70+

Entry zone post-Q2 GO: EUR 45-50 = ATR-1 below current = forward 14-15x.

The Graham value here is real — but right now, with Q1 miss + AQR short + governance fight, the asymmetric risk is to the downside on a 3-month horizon. Patience captures the same thesis with better margin of safety.

Framework Reasoning #

Graham (Quantitative) #

• 4/7 defensive filters. Trailing P/E 19.6x stretches the ≤20x threshold (passes). Forward P/E 15.8x clears the same bar.
• Break-even growth: 3.7% on forward EPS. Indra has grown net income at 36% CAGR FY2022-2025. Even normalizing for low base effects, 15-20% sustained EPS growth is achievable.
• Net cash EUR 835M provides modest balance sheet cushion.

Klarman (Downside) #

• Q2 miss scenario → guidance cut → re-rating to forward 12-13x → EUR 40 (-21%)
• Governance crisis (Escribano hostile action, SEPI counter-action) → EUR 33-35 (-30 to -35%)
• Defense margin proves PEM-prepayment-inflated → re-rate to 14% group margin → EUR 38-42 (-17 to -25%)

Lynch Classification #

• Cyclical fast grower at structural inflection. Defense cycle just turning up. Lynch would warn against paying for cyclical peak earnings — but the EUR 20B backlog argues this is multi-year, not single-year cyclical.

Insider Signal (shr-002) #

• No disclosed CEO/CFO/director open-market purchases in last 30 days.
• CEO compensation is heavily equity-based (74% bonus/equity), but no open-market buys.
• SEPI (state) cannot signal conviction through buying — they're already 25.16% owner.
• Escribano family is in board dispute mode, not buying mode.
• NET SIGNAL: AMBER-RED. Absence of insider buying + AQR shorting is a coherent bearish data point.

Red Flags #

1. Q1 revenue miss combined with AQR short = informed bearish signal. The market reaction was modest (-4%) but the signal is real.

2. Defense margin 18.1% may be PEM-prepayment-inflated. Spanish PEM programs include large advance payments (EUR 1.67B in Q1 alone). Recognizing revenue while holding cash creates favorable working capital arithmetic but the sustainable margin once prepayments stabilize is untested.

3. Adjusted FCF Q1 was -EUR 40M. The headline EUR 1.44B is 100% explained by Spanish PEM cash advances. The clean operating cash flow is negative for the quarter.

4. Governance: Escribano vs SEPI board fight. Both 25.16% and 14.3% holders can disrupt board composition. The settlement may favor minority shareholders (governance improvement) or it may distract management for 6-12 months.

5. Spanish political instability. PSOE-Sumar minority government is fragile. Snap election risk would delay PEM contract execution.

6. Dividend was suspended 2016-2021. A re-suspension under SEPI pressure (if government needs budget) is a precedent risk.

7. Spanish FTT 0.2% on entry + DEGIRO commission ~EUR 3.50 = ~0.9% round-trip friction on small positions.

Decision Rule (Post Q2 Results) #

GO conditions (all must be met):

• Q2 Defense revenue ≥ EUR 700M (validates H1 > EUR 1B mgmt guidance)
• EBIT margin maintained ≥ 11% at group level
• 2026 guidance reaffirmed (>EUR 7.0B revenue, >EUR 700M EBIT)
• Escribano governance dispute settled or de-escalated

NO-GO conditions (any one triggers):

• Q2 Defense revenue < EUR 600M (structural delay, not timing)
• 2026 guidance cut
• Further AQR short increase post-Q2
• Escribano lawsuit / hostile board action
• PSOE government collapse / snap election announced

If GO: deploy T1 (5 shares, ~EUR 250) at EUR 47 or current price, whichever lower. T2 of 5 shares at EUR 42 retest.

If NO-GO: archive thesis, redeploy budget. Defense thesis can be expressed via AM.PA instead.

Bottom Line #

Indra has the strongest long-term defense growth profile in the screen — EUR 20B backlog, 18% Defense EBIT margin, sector-leading orders. But:

• Q1 revenue miss creates a binary verification event in ~10 weeks (Q2 2026)
• AQR's informed short and Escribano governance fight are coherent risk signals
• Forward P/E 15.8x is cheap if growth holds; expensive if growth stalls
• Patience captures the same Graham asymmetry with better margin of safety post-Q2

Recommendation: DEFER. Re-evaluate at Q2 2026 results late July/early August 2026.

Capital that would have gone here can be redirected to:

• AM.PA T2/T3 if it retests EUR 260-265
• QQ.L T1 if May 21 results validate guidance
• Existing satellite (AGN.AS/RI.PA) per shr-019 (never sell core to fund satellite, but monthly contributions can rebalance)

Monitoring Plan #

• Late July / early August 2026: Q2 2026 results — apply GO/NO-GO decision rule
• Pre-Q2 watch items: Escribano board-seat resolution, SEPI dividend policy statements, EDF/SAFE contract conversions
• Set alert: IDR.MC-Q2-DECISION (manual review late July/August 2026)